Cintas’ FY27 guide is healthy; its price still leaves no 10/5 margin

Summary: Cintas enters its Q1 FY2027 release after record FY2026 gross margin, 8.3% organic revenue growth, and an adjusted-EPS guide of $5.36–$5.50. But at the September 22 close of $198.80, the midpoint guide implies 36.6x adjusted earnings. A transparent sensitivity map places the highest-probability case essentially flat to modestly down, with a credible adverse case near -19%; only the optimistic combination of high-end EPS and a re-rating clears +10%. Reject the long at this reference price. This is an earnings-risk screen, not an order or a request to wait for market hours.

Opportunity Ranking

Rank	Candidate	Direction	Mispricing	Evidence Freshness	Catalyst Window	Positioning	10/5 Status	Tradeability
1	Cintas (CTAS)	Long	Durable service growth versus a 36.6x FY27 adjusted-EPS midpoint multiple ahead of Q1 results	FY2026 issuer release July 15; Q1 release scheduled Sep. 23; Sep. 22 close	Q1 FY2027 results and 10:00 a.m. ET call; UniFirst regulatory process	Current ownership/short/option flows unknown	Highly traded Nasdaq common; live execution checks unavailable	High expectations may already capitalize organic growth and the premium may compress on a guide miss
2	Paychex (PAYX)	Long	Strong HR/payroll cash engine versus 5–9% FY27 growth guide and post-Paycor leverage	FY2026 issuer filing June 24; Q1 call scheduled Sep. 23; Sep. 22 close	Q1 results and 9:30 a.m. ET call	Current positioning unknown	Liquid Nasdaq common; current spread/depth unverified	Integration, debt and slower growth may cap repricing despite a lower multiple
3	Manchester United (MANU)	Long	Raised FY26 revenue/EBITDA guide versus sport-dependent revenue, debt and thin trading	Q3 6-K May 27; Q4 report scheduled Sep. 23; Sep. 22 close	Full-year FY2026 release scheduled 7:00 a.m. Eastern	Current positioning unknown	NYSE listing, but 287,502 shares reported Sep. 22	Match performance and broadcast revenue can reverse quickly; exit quality is unverified

Selected opportunity: CTAS, for information value only; it is not a qualifying long.

Why this one now: Cintas combines the clearest primary operating record and a dated near-term catalyst with the richest measurable valuation hurdle in the comparison. The evidence supports a strong business; it does not show enough expected price upside from this close to compensate for earnings and valuation risk.

What should surprise the reader: The company’s $5.36–$5.50 FY2027 adjusted-EPS range represents roughly 8.5%–11.3% growth from FY2026 adjusted EPS of $4.94, while $198.80 values the midpoint at about 36.6 times. A good company and a good business outlook do not automatically leave a good entry price.

Why This Is the Best Opportunity Right Now

This is the highest-information long screen among three U.S.-listed companies reporting today, not the best executable opportunity. CTAS offers a clear bridge between current price, issuer guidance and a same-day results test. Paychex has a lower indicated multiple, about 20.8x FY2026 adjusted EPS at its $114.53 September 22 close, but guides only 5%–6% revenue growth and 7%–9% adjusted-EPS growth as it integrates Paycor and carries $4.6 billion of borrowings. Manchester United has a raised FY2026 outlook, but its results depend materially on competition and broadcast economics, and its September 22 volume was 287,502 shares. Paychex FY2026 results · PAYX historical price · Manchester United Q3 FY2026 results

The strongest counterparty case is compelling: Cintas reported 8.3% organic growth, a record 50.7% full-year gross margin, 23.1% operating margin, and 12.3% growth in adjusted diluted EPS for FY2026. The upcoming Q1 can confirm whether route density, cross-selling and service reliability continue supporting growth. Cintas FY2026 results

This screen differs from the Desk’s May UniFirst article. That article examined a long-UNF / short-CTAS merger spread; this one evaluates unhedged CTAS as a standalone equity against its new FY2026 results, FY2027 guidance and Q1 catalyst. The UniFirst transaction remains a risk and possible upside, but its economics are excluded from the issuer’s current FY2027 guide.

Why This Can Move More Than 5% Soon

Cintas will release fiscal Q1 FY2027 results on September 23 and webcast its call at 10:00 a.m. Eastern. The September 22 regular close is the price basis; the Q1 release was not present in the checked investor-relations feed at this run time. Cintas Q1 event notice

The release can change expectations for organic growth, wage/route costs, gross and operating margins, and the year’s EPS range. One independent earnings calendar shows Q1 consensus of $1.35 per diluted share and $2.98 billion revenue; that is analyst consensus, not company guidance. The company’s own FY2027 guide is $12.10–$12.25 billion of revenue and $5.36–$5.50 adjusted diluted EPS. It excludes expected revenue/EPS from the proposed UniFirst acquisition, even as bridge-financing amortization raises the interest assumption. UniFirst shareholders approved the deal, but both companies received an FTC second request; Cintas said it still expected a close in the second half of calendar 2026. Cintas FY2026 results and outlook · Q1 estimate snapshot

10/5 Asymmetry Gate

Input	Result
Reference price	$198.80, Nasdaq regular-session close, Sep. 22, 2026
FY2027 adjusted-EPS midpoint	$5.43
Price / guide midpoint	36.61x
Base scenario	$198.74 (36.6x midpoint), -0.03%
Credible adverse scenario	$160.80 (30x low-end guide), -19.09%
Gross reward / adverse risk	0.00:1; base is not positive
Probability-weighted price	$193.51; -2.66% before costs
10/5 status	Reject

Only the top scenario clears +10%; the highest-probability case is essentially flat and the credible adverse case exceeds -5%. A 10% price gain from $198.80 is $218.68. At the $5.43 midpoint, that requires 40.27x adjusted EPS; at the top-end $5.50 guide, it still requires 39.76x. A reference-only screen cannot qualify as a trade.

What Should Surprise the Reader

The guide does not include the proposed UniFirst acquisition’s expected revenue or EPS, and it does not include future buybacks. At the same time, Cintas says FY2027 interest expense net of interest income will rise to about $105 million from $101.2 million, mainly from bridge-loan financing-cost amortization. The acquisition could create value, but its future earnings contribution cannot be counted as current guidance or treated as a completed state. The FTC second request remains part of the path.

The Setup

Observed: CTAS closed at $198.80 on September 22, up 0.98%, with about 2.23 million shares traded. The market-data provider labels that a regular-session close at 4:00 p.m. EDT. CTAS historical price data

Observed: FY2026 revenue reached $11.26 billion, organic growth was 8.3%, adjusted diluted EPS was $4.94, and operating cash flow was $2.28 billion. Cintas guided FY2027 revenue of $12.10–$12.25 billion and adjusted diluted EPS of $5.36–$5.50, excluding UniFirst transaction impacts and future share repurchases.

Inference: The price implies investors expect this durable growth and margin profile to persist. No direct current ownership or positioning data were verified; price and volume alone do not establish crowding.

The Market Price

The model uses the latest completed regular-session close, $198.80 at 4:00 p.m. EDT on September 22. The reference data report a day range of $196.00–$198.81 and volume of about 2.23 million. No pre-market indication, live spread, depth, venue-quality, volume-quality or exit-liquidity snapshot is used.

Using Cintas’ adjusted-EPS guidance midpoint, $198.80 / $5.43 = 36.61x. This is a reference multiple built from company guidance, not an analyst-consensus fair value. The FY2027 guidance itself represents about 9.9% midpoint adjusted-EPS growth over FY2026’s $4.94.

The Mispricing

The disagreement is between price and the growth actually guided. CTAS is a high-quality recurring-service business: FY2026 organic revenue rose 8.3%, gross margin reached a record 50.7%, and operating margin increased to 23.1%. At 36.6x midpoint adjusted EPS, investors appear willing to pay for that durability. The uncertainty is whether Q1 results or future guide changes create upside beyond what is already reflected in that multiple.

The market may be right if organic growth stays near the high-single digits, margins remain at record levels, and UniFirst closes with attractive synergies. It may be wrong if labor, route and integration costs constrain conversion, Q1 growth is below the high expectations embedded in a 36.6x multiple, or FTC timing delays the acquisition while financing expenses accrue.

Load-bearing assumption: The FY2027 guidance midpoint is a reasonable one-year earnings anchor. The cheapest falsification test is today’s Q1 report and call: compare organic revenue growth, operating margin, cash conversion and management’s guide range with the company’s own assumptions.

The Positioning

Positioning is unknown. The close volume of 2.23 million shares provides liquidity context but does not reveal who owns the stock, whether it is hedged, or whether any flow is forced. Current short interest, borrow, options positioning and fund flows were not verified. Positioning score: 2/5.

The Catalyst

Q1 FY2027 results and call, September 23: check revenue against $12.10–$12.25 billion annual guidance, organic growth, gross/operating margins, EPS, labor and route cost trends. The webcast is scheduled for 10:00 a.m. ET.
FY2027 guide updates: require an explicit change to the current $5.36–$5.50 adjusted-EPS range, not a generalized confidence statement.
UniFirst process: monitor the FTC second request and closing conditions. Until closing, record no acquisition revenue or synergy as earned; assess bridge financing and transaction-cost carry.
Cash and capital return: check operating cash flow, capex, actual repurchases and dividend separately. Guidance excludes future buybacks.

The Payoff

This reference-only sensitivity applies explicit P/E assumptions to the issuer’s FY2027 adjusted-EPS range. It does not use an external peer multiple, claim a historical valuation norm, or include an assumed acquisition contribution. The top case pairs high-end EPS with a 40x multiple; the base holds midpoint EPS but compresses the multiple slightly to 36.6x; the bottom pairs the low guide with a 30x stress multiple. Probabilities (20% / 55% / 25%) are subjective analyst estimates, not historical frequencies: the high base probability reflects operating durability, while the top case is conditional on an upside surprise and the bottom case captures ordinary high-multiple de-rating plus execution disappointment.

The probability-weighted reference price is below the current close before spread or slippage. Since the economics fail before costs and current execution conditions are unavailable, the signal remains blocked.

Price Target and Probability Map

Scenario	Probability	Target / Level	Return / Payoff	Horizon	Conditions	Evidence Quality
Top Case	20%	$220.00 (40x $5.50 high-end FY27 guide)	+10.66%	Through FY2027 results, approx. 9 months	Q1 beats, company raises/affirms upper end, margins remain strong; market sustains a 40x valuation	Low
Base Case	55%	$198.74 (36.6x $5.43 midpoint)	-0.03%	Through FY2027 results	Midpoint guide achieved, but no meaningful re-rating	Medium
Bottom Case	25%	$160.80 (30x $5.36 low-end guide)	-19.09%	Through FY2027 results	Q1 disappoints or outlook slips; acquisition delay/costs and multiple compression outweigh recurring growth	Low
Invalidation	n/a	Strong Q1 results accompanied by raised standalone guidance and a resolved, funded UniFirst path	Long-screen rejection invalidated	Q1 call / later transaction milestones	Verify filed results, regulatory milestones, financing and updated diluted share count	Medium

Probability-weighted expected value: $193.51, or -2.66% versus the $198.80 reference, before costs.

Current market level and timestamp: $198.80 regular-session close, September 22, 2026, 20:00 UTC.

Primary instrument: CTAS common stock, unlevered; no trade proposed.

10/5 favorable base move: -0.03% (fails +10%).

10/5 credible adverse move: -19.09% (fails -5%).

10/5 measurement basis: reference-only regular close; no executable entry.

10/5 status: Reject.

Confidence: Low. Company operating and guidance data are primary; scenario multiples and subjective probabilities are assumptions, and current positioning/market microstructure are unknown.

Sensitivity and break-even

At the $5.43 midpoint, each 1x change in P/E moves the model price by $5.43, or 2.73% of the reference. A +10% target requires 40.27x midpoint EPS; even the $5.50 top of guidance requires 39.76x. A 10% EPS miss at a 36.6x multiple gives about $179.00 (-9.9%); this illustrative stress is worse than the Desk’s -5% adverse bound. These are price sensitivities, not forecasts.

The Kill Shot

The mature counterparty case is that Cintas’ reported record gross margin and 8.3% organic growth are structural: outsourcing workplace functions is recurring, routes are dense, and cross-selling can raise wallet share without proportional labor or capital. If today’s Q1 release sustains that pattern, a 36.6x forward multiple may persist or expand.

The weak point in the rejection is the scenario multiple, not the company’s operating evidence. The 30x bottom is a low-confidence stress, not a peer-validated floor. Still, a long must be attractive on the highest-probability path, and this model has no base upside at today’s close. The May UniFirst spread article assessed a different security pair and antitrust spread; this article does not reuse that thesis or propose a CTAS hedge.

What Could Go Wrong

The share price can gap on Q1 results, a guidance change, a new UniFirst antitrust development or acquisition financing. Wage inflation, route costs, workday mix, service retention and integration costs can change margin conversion. The valuation can compress even if the business meets guidance. A five-percent stop cannot protect an overnight gap; current spread, depth and exit liquidity remain unverified.

What Would Prove This Wrong

The no-trade conclusion should be revisited if Q1 shows organic growth above the FY2026 8.3% rate with stable or higher 23.1% operating margin, management raises standalone adjusted EPS guidance beyond $5.50, and the UniFirst regulatory path advances with financing and share dilution fully modeled. A revenue beat alone is insufficient.

Risk Audit

Classification: Reject / no-trade screen, not Watchlist; the modeled base and adverse paths fail 10/5.
Fact versus inference: FY2026 actuals and FY2027 guidance are issuer-reported; the price/EPS ratio is derived; P/E scenario assumptions are analyst sensitivities.
Positioning: unknown; no short or flow-based crowding claim is made.
Residual risks: earnings gap, valuation compression, labor and service costs, acquisition/regulatory delay, financing, integration and unverified exit liquidity.
Execution: entry.price is null and execution.can_execute is false. No options, leverage, margin, market order or price-floor logic.

Best Trade Strategy

No trade. Revisit after the Q1 report and first regular-session price acceptance only if the updated guide and valuation create a positive 10/5 map. Live quote, spread, depth, venue, volume quality and exit liquidity must be verified before any hypothetical entry.

Sources

Cintas FY2026 Q4 and full-year results and FY2027 guidance, issuer release, July 15, 2026.
Cintas Q1 FY2027 results schedule, issuer release, September 9, 2026.
CTAS regular-session price history, September 22, 2026 close; market data.
CTAS market-cap snapshot, September 22, 2026; third-party market data.
Paychex Q4 FY2026 results and FY2027 outlook, issuer release filed June 24, 2026.
Paychex Q1 FY2027 call schedule, issuer release, September 9, 2026.
PAYX September 22 close, market data.
Manchester United Q3 FY2026 results, issuer release filed May 27, 2026.
Manchester United Q4 FY2026 report date, issuer 6-K filed September 9, 2026.
MANU September 22 close, market data.
September 23 EPS and revenue estimate calendar, third-party consensus data; used only for candidate comparison, not target construction.

Research Quality Scorecard

Criterion	Score	Reason
Market disagreement	4/5	Premium forward multiple versus ~10% guided EPS growth and a near-term test
Evidence base	4/5	Fresh price and confirmed Q1 event, but Q1 results are not yet in the reviewed issuer feed
Positioning and flows	2/5	Current ownership, options and flow evidence unavailable
Catalyst path	5/5	Q1 release/call and formal FY27 guide provide an observable test
Payoff architecture	2/5	Base is approximately flat; adverse case breaches downside bound
Invalidation discipline	4/5	Organic growth, margin, guide, deal status and financing are observable
Differentiated insight	4/5	The deal is excluded from the guide while financing costs already affect the standalone forecast
Client value	4/5	Separates business quality, deal optionality and what today’s price requires

Total: 29/40. Publishable as a no-trade screen; the score does not override failed 10/5 economics.

Bottom Line

Cintas is an excellent operating business, but at $198.80 its FY2027 midpoint guide already trades at 36.6x adjusted EPS. The base case is flat, and a credible high-multiple de-rating creates a loss well beyond 5%. Upside above 10% requires both high-end results and a premium valuation. Reject the long at this reference; revisit only after the report, guide and price are known.

AI Illustration Prompt

Editorial illustration of a Cintas service route map and uniform/facility-services checklist leading into an earnings folder marked “FY27 ADJUSTED EPS $5.36–$5.50”; place a valuation gauge at “36.6× MIDPOINT” beside a clear fork between “GUIDE RAISE” and “MULTIPLE COMPRESSION,” with a separate sealed folder labelled “UNIFIRST: PENDING FTC”; polished documentary style, deep navy, warm paper and restrained red/green, no chart prediction or trading terminal, subtle readable “The Mispricing Desk” watermark.